A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma

Condition: Advanced Hepatocellular Carcinoma

Sponsor: Kintor

A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma. To evaluate the efficacy of GT90001 in combination with Nivolumab compared with Nivolumab in patients with aHCC who had progressed after or intolerant to first-line treatment with a tyrosine kinase inhibitor.


Go To Trial Homepage